genryzon-red-flag-monitoring

name

genryzon-red-flag-monitoring

description

Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

Genryzon Red-Flag Monitoring

Safety net for a child already on somatrogon. Walk this scan at every follow-up visit and any time the family reports a new symptom.

---

Step 1 — Symptom-triggered scan at every visit

Ask the family (and the child directly if age-appropriate) about each of the following since the last visit. Any positive → move to the matching Step 2 workup.

Symptom	Suspect
Persistent headache; vision changes; nausea/vomiting; papilloedema	Benign intracranial hypertension
New limp; hip pain; knee pain (referred from hip)	Slipped capital femoral epiphysis (SCFE)
Severe or persistent abdominal pain	Pancreatitis
Localised injection-site myalgia; disproportionate pain at injection sites	Myositis (m-cresol excipient)
Back curvature progression; asymmetry of shoulders/hips; scoliosis on inspection	Scoliosis progression
New neurological symptom in a childhood cancer survivor with prior cranial radiation	Second neoplasm (esp. meningioma)
Polyuria, polydipsia, weight loss, or rising HbA1c	Somatrogon-induced hyperglycaemia
Fatigue, hypotension, weight loss, hypoglycaemia, hyponatraemia	Unmasked central hypoadrenalism
Fatigue, cold intolerance, constipation, poor growth despite therapy	Unmasked central hypothyroidism
New hypersensitivity: rash, angioedema, wheeze, anaphylaxis	Systemic hypersensitivity

---

Step 2 — Specific workup and immediate action per red flag

Benign intracranial hypertension (IH)

Workup:

• Fundoscopy — look for papilloedema
• Neurological exam
• CT/MRI brain to exclude a mass
• If exam consistent with IH → LP for opening pressure (per neurology)

Action:

• Temporarily discontinue somatrogon
• Refer to neurology / neuro-ophthalmology
• Restart cautiously only after resolution, with close monitoring. There is no consensus rule for restart timing; document the joint decision with neurology

Slipped capital femoral epiphysis (SCFE)

Workup:

• Urgent hip / knee X-ray (AP and frog-lateral of both hips)
• Refer to paediatric orthopaedics

Action:

• Non-weight-bearing until orthopaedic review — SCFE can worsen with continued weight-bearing
• Somatrogon can generally be continued once SCFE is managed, but discuss with orthopaedic team

Pancreatitis

Workup:

• Serum lipase and amylase
• Ultrasound / CT abdomen if levels elevated or persistent pain
• Look for other precipitants (gallstones, hypertriglyceridaemia, drugs)

Action:

• Hold somatrogon during acute episode
• Standard pancreatitis management (fluids, pain control, NPO if severe)
• Restart only after full resolution, with careful monitoring

Injection-site myositis (m-cresol)

Workup:

• Clinical assessment — disproportionate pain, tenderness, swelling at injection sites
• CPK if diffuse myalgia
• MRI of affected muscle if severe or persistent

Action:

• Switch to a metacresol-free growth hormone product (m-cresol is the preservative in Genryzon)
• Local supportive care

Scoliosis progression

Workup:

• Adam's forward bend test
• Standing spinal X-ray (Cobb angle)
• Refer to paediatric orthopaedics / spinal team if Cobb ≥20° or rapid progression

Action:

• Somatrogon can generally be continued — GH does not directly cause scoliosis but rapid growth may reveal or worsen it
• Manage the scoliosis per orthopaedic protocol (bracing, surgery as indicated)

Second neoplasm — childhood cancer survivors

Focus on:

• Cranial radiation history → meningioma is the most-reported second tumour on GH
• New neurological symptom, headache, cranial nerve deficit, focal deficit → MRI brain
• Any suspicious skin or somatic lump → biopsy per oncology

Action:

• Loop oncology in early for any concerning symptom
• Adhere to the survivor's baseline surveillance schedule
• If second neoplasm is confirmed → discontinue somatrogon and manage the neoplasm

Somatrogon-induced hyperglycaemia

Workup:

• Fasting plasma glucose + HbA1c
• OGTT if borderline

Action:

• Diabetes at diagnosis → involve paediatric diabetologist; escalate insulin/OAD as needed. Somatrogon can usually continue but with tight glucose monitoring
• Pre-diabetes → lifestyle intensification, monitor more frequently
• Insulin-treated child already → up-titrate insulin doses as needed

Unmasked central hypoadrenalism

Workup:

• Morning cortisol
• ACTH stimulation test / ITT if borderline

Action:

• If adrenal crisis suspected → treat as adrenal crisis first: IV hydrocortisone, IV fluids, glucose. Investigate afterwards
• If confirmed central hypoadrenalism → start (or escalate) hydrocortisone replacement. Continue somatrogon
• If child already on hydrocortisone replacement → dose may need to be increased on GH (GH ↓ cortisone→cortisol conversion)

Unmasked central hypothyroidism

Workup:

• TSH + free T4 (interpret carefully — in central hypothyroidism, TSH may be normal or inappropriately low despite low fT4)

Action:

• Start or up-titrate levothyroxine — untreated hypothyroidism blunts response to GH
• Recheck TFTs 6–8 weeks after any thyroxine change

Systemic hypersensitivity

Action:

• Immediately discontinue Genryzon
• Standard anaphylaxis management (adrenaline IM, airway support, IV fluids, corticosteroids, antihistamines)
• Do not rechallenge — switch to a somatrogon-free growth hormone product after specialist review

---

Step 3 — Scheduled monitoring at every 6–12 month visit (more often in puberty)

Even without new symptoms, at each planned visit check:

• Auxology: height, weight, height velocity (cm/yr), BMI
• Bone age — annually or as indicated
• Tanner stage
• IGF-1 (day 4 post-dose — see genryzon-igf1-titration)
• TSH + free T4
• Fasting glucose ± HbA1c
• Fundoscopy if any suspicious symptom
• Spinal inspection for scoliosis
• Pubertal progression and, in girls, review of oral estrogen / OCP use

---

Guardrails

• Headache in a child on somatrogon is intracranial hypertension until proven otherwise — do not attribute to common causes without a fundoscopy
• Any limp or hip/knee pain in a child on GH warrants a same-week hip X-ray for SCFE — this diagnosis is regularly missed and delayed diagnosis worsens the outcome
• Injection-site myalgia is not "normal soreness" — it can be m-cresol myositis and mandates a switch of GH product
• Childhood cancer survivors on GH need active surveillance for second neoplasm — a neurological complaint is never "just growing pains" in this group
• Adrenal crisis can present as vague fatigue and abdominal pain — a low threshold for morning cortisol / stress-dose steroids in any child on GH who becomes unwell
• Never dismiss papilloedema on baseline fundus and continue GH — that's a signal that pre-existing IH was missed and now the drug will worsen it
• Somatrogon does not need to be permanently stopped for most of these events — most can be resumed after the underlying issue is addressed, except confirmed second neoplasm and severe hypersensitivity, which are absolute stops

---

Related MD2SKILL skills

• genryzon-prescribing-guide — starting dose, injection technique, monitoring cadence
• genryzon-igf1-titration — how to interpret and act on IGF-1 SDS
• genryzon-pretreatment-screening — baseline work-up before first dose
• genryzon-drug-interactions — glucocorticoid, insulin, thyroxine, oral estrogen adjustments
• genryzon-treatment-discontinuation — when to stop growth hormone entirely

---

Source

Pfizer Products India Pvt. Ltd. GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India). LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.4 "Special Warnings and Precautions for Use" and Section 4.8 "Undesirable Effects".